Seeking Alpha

Aegerion Pharmaceuticals (AEGR +8.5%) says the FDA has provided a clear and executable pathway...

Aegerion Pharmaceuticals (AEGR +8.5%) says the FDA has provided a clear and executable pathway for the company to file a New Drug Application for its lead investigational therapeutic, lomitapide, based upon Phase III clinical trial results in 29 patients with HoFH, with a primary endpoint of LDL-C reduction.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs